© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Coherus BioSciences, Inc. (CHRS) stock declined over -0.76%, trading at $1.31 on NASDAQ, down from the previous close of $1.32. The stock opened at $1.35, fluctuating between $1.29 and $1.45 in the recent session.
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Employees | 235 |
Beta | 0.69 |
Sales or Revenue | $257.24M |
5Y Sales Change% | 113.144% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Coherus BioSciences, Inc. (NASDAQ: CHRS) stock price is $1.31 in the last trading session. During the trading session, CHRS stock reached the peak price of $1.45 while $1.29 was the lowest point it dropped to. The percentage change in CHRS stock occurred in the recent session was -0.76% while the dollar amount for the price change in CHRS stock was -$0.01.
The NASDAQ listed CHRS is part of Biotechnology industry that operates in the broader Healthcare sector. Coherus BioSciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Karen Kotz
Executive Vice President of Sales & Strategic Accounts
Mr. Bryan J. Mcmichael
Senior Vice President of Accounting, Principal Accounting Officer & Corporation Controller
Mr. Richard L. Hameister
Chief Technical Officer
Mr. Christopher W. Slavinsky
Chief Bus. & Legal Officer
Mr. Dennis M. Lanfear
Chairman, Pres & Chief Executive Officer
Mr. Vladimir Vexler Ph.D.
Chief Scientific Officer
Mr. McDavid Stilwell
Chief Financial Officer
Cheston Turbyfill
Vice President of Communications
Dr. Lee Mermelstein Ph.D.
Executive Vice President of Manufacturing
Ms. Rebecca Sunshine
Chief HR Officer
Mr. Paul Reider
Chief Commercial Officer
CHRS's closing price is 98.48% higher than its 52-week low of $0.66 where as its distance from 52-week high of $2.87 is -54.35%.
Number of CHRS employees currently stands at 235.
Official Website of CHRS is: https://www.coherus.com
CHRS could be contacted at phone 650 649 3530 and can also be accessed through its website. CHRS operates from 333 Twin Dolphin Drive, Redwood City, CA 94065, United States.
CHRS stock volume for the day was 2.88M shares. The average number of CHRS shares traded daily for last 3 months was 5.08M.
The market value of CHRS currently stands at $151.45M with its latest stock price at $1.31 and 115.61M of its shares outstanding.